92 research outputs found
Effects of moderate smoking on arterial elasticity in healthy European population. The seven European sites study of arterial elasticity
No full textEffects of family history on arterial elasticity in healthy European population-The seven european sites study of arterial elasticity (AE).
No full textEffects of modest wine/beer drinking on arterial elasticity in healthy european population. The seven european sites study (SESS)
No full textThe seven european sites study of arterial elasticity. Using the blood pressure waveform analysis reliability, repeatability and establishment of normal values for healthy European population with comparison to healthy US population
No full textEffects of family history of hypertension and CVA on arterial elasticity in healthy European population. The seven European sites study of arterial elasticity (AE).
No full textDetermination of arterial compliance using blood pressure waveform analysis with the CR-2000 system: Reliability, repeatability, and establishment of normal values for healthy European population--the seven European sites study (SESS).
No full textN017 Hemodynamic (HD) change at rest and activity during weight loss in morbidly obese hypertensive patients
No full textDifferential clinical profile of candesartan compared to other angiotensin receptor blockers
No full textRelu Cernes1,2, Margarita Mashavi1,3, Reuven Zimlichman1,31The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel; 2Department of Nephrology, Wolfson Medical Center, Holon, Israel; 3Department of Medicine, Wolfson Medical Center, Holon, IsraelAbstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, efficacy studies, safety, blood pressur
Hyperinsulinemia Induces Myocardial Infarctions and Arteriolar Medial Hypertrophy in Spontaneously Hypertensive Rats
No full textRest and Effort Hemodynamic Responses During Prolonged Treatment With Felodipine, 24-h Blood Pressure Monitoring, and Echocardiographic Changes
No full text- …
